HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Septo-optic dysplasia sequence — Clinical Guidelines

Overview

Septo-optic dysplasia (De Morsier syndrome) is characterized by optic nerve hypoplasia, midline brain malformations including absence of the septum pellucidum, and hypothalamic-pituitary dysfunction 1 3 6.

Diagnosis

Key Diagnostic Criteria: Optic nerve hypoplasia, absence or hypoplasia of the septum pellucidum, and hypothalamic-pituitary dysfunction 1 3 6 7.

Recommended Tests:

- Ophthalmological Evaluation: Fundus examination to assess optic nerve hypoplasia 3. - Neuroimaging: MRI to identify midline brain malformations such as absence of the septum pellucidum and schizencephaly 7. - Endocrine Assessment: Evaluate growth hormone, thyroid-stimulating hormone (TSH), cortisol, and gonadotropins to detect hormonal deficiencies 4 6 9.

Grading: Diagnosis often requires the presence of at least two out of the three primary features; incomplete forms exist with fewer criteria met 5.

Management

First-Line Treatments:

- Hormone Replacement Therapy: Address specific deficiencies identified (e.g., growth hormone, thyroid hormone, cortisol, sex hormones) 4 6 9. - Monitoring: Regular follow-up for growth, development, and hormonal levels 6.

Adjunctive Treatments:

- Vision Support: Early intervention for visual impairment 10. - Neurodevelopmental Support: Psychological and neurological support based on functional involvement 3.

Special Populations

Pediatrics: Early diagnosis and multidisciplinary care are crucial for optimal development 3 6.

Comorbidities: Young, nulliparous mothers are noted in some cases, suggesting potential maternal factors 9.

Key Recommendations

Comprehensive Evaluation: Include ophthalmological, neuroimaging, and endocrine assessments for accurate diagnosis 3 6 7 (Evidence: Strong).

Multidisciplinary Care: Implement a team approach involving endocrinologists, ophthalmologists, neurologists, and developmental specialists 3 6 (Evidence: Moderate).

Individualized Hormone Replacement: Tailor hormone replacement therapy based on specific endocrine deficiencies identified 4 6 9 (Evidence: Moderate).

References

1 Spinosa MJ, Liberalesso PB, Vieira SC, Löhr A. De Morsier syndrome associated with periventricular nodular heterotopia: case report. Arquivos de neuro-psiquiatria 2007. link 2 Makhoul IR, Aviram-Goldring A, Paperna T, Sujov P, Rienstein S, Smolkin T et al.. Caudal dysplasia sequence with penile enlargement: case report and a potential pathogenic hypothesis. American journal of medical genetics 2001. link99:1<54::aid-ajmg1124>3.0.co;2-f) 3 Hellström A, Aronsson M, Axelson C, Kyllerman M, Kopp S, Steffenburg S et al.. Children with septo-optic dysplasia - how to improve and sharpen the diagnosis. Hormone research 2000. link 4 Nanduri VR, Stanhope R. Why is the retention of gonadotrophin secretion common in children with panhypopituitarism due to septo-optic dysplasia?. European journal of endocrinology 1999. link 5 Furujo M, Ichiba Y. Two cases of Septo-optic dysplasia (SOD). Endocrine journal 1998. link 6 Willnow S, Kiess W, Butenandt O, Dorr HG, Enders A, Strasser-Vogel B et al.. Endocrine disorders in septo-optic dysplasia (De Morsier syndrome)--evaluation and follow up of 18 patients. European journal of pediatrics 1996. link 7 Barkovich AJ, Fram EK, Norman D. Septo-optic dysplasia: MR imaging. Radiology 1989. link 8 Sirota L, Dickerman Z, Laron Z, Weitz R, Dulitzky F. Neuroendocrine study of a male infant with septo-optic dysplasia. Israel journal of medical sciences 1985. link 9 Izenberg N, Rosenblum M, Parks JS. The endocrine spectrum of septo-optic dysplasia. Clinical pediatrics 1984. link 10 Acers TE. Optic nerve hypoplasia: septo-optic-pituitary dysplasia syndrome. Transactions of the American Ophthalmological Society 1981. link 11 Patel H, Tze WJ, Crichton JU, McCormick AQ, Robinson GC, Dolman CL. Optic nerve hypoplasia with hypopituitarism. Septo-optic dysplasia with hypopituitarism. American journal of diseases of children (1960) 1975. link

Septo-optic dysplasia sequence